Posts Tagged ‘nasdaq’

CTI Industries Corp. (CTIB) – Buzz Stock of the Day

Friday, April 30th, 2010


Shares of CTI Industries Corp. (Nasdaq: CTIB) were up as much as 79 percent from yesterday’s close in morning trading after the company announced first quarter earnings of $599,000 or 22 cents per share, up 544 percent from the same period a year ago, driven by higher sales of its pouch and novelty products, and a 3 percent increase in gross margin.


Revenue for the quarter was up 29 percent to $12.4 million, from $9.6 million in the same quarter a year ago.


Sales of pouch products were up 208 percent from $986,000 in the first quarter 2009 to $3,041,000 in the first quarter of 2010. Most of this increase was a reflection of strong continuing sales of zippered vacuumable pouches to a principal customer. Sales of CTI’s proprietary ZipVac™ line of vacuumable pouches also increased.

Novelty product revenues were up 18.6 percent, from $6,580,000 in the first quarter of 2009 to $7,804,000 in the first quarter of 2010. Sales of laminated films showed a modest decline from $1,876,000 in the first quarter of 2009 to $1,367,000 in the first quarter of 2010.

Gross margins increased to 24.5 percent in the first quarter of 2010 compared to 21.5 percent for the first quarter of 2009. This increase is the result of increased production and sales volume during the first quarter of 2010 resulting in lower unit cost than in the same period of 2009 and a change in the mix of products sold to certain novelty and pouch products having a higher margin.

Click here to join the chatter and find out what others are saying about CTIB at its official Buzz Stock board!

Sinoenergy Corp. (Nasdaq: SNEN) Buzz Stock of the Day

Monday, October 12th, 2009

Shares of Chinese natural gas developer Sinoenergy Corp. (Nasdaq: SNEN) ) rose 53 cents, or 41.5 percent, to $1.81 in morning trading Monday after the company announced that it will be taken private through a merger with Skywide Capital Management Ltd.

Skywide, which is owned by Sinoenergy chairman, Tianzhou Deng, and its president, Bo Huang, is Sinoenergy’s largest shareholder, holding 39.06 percent of the company’s outstanding common stock.
Shareholders of Sinoenergy will receive $1.90 per-share when the merger is completed. That amounts to a total value of about $30.3 million, a 48.4 percent premium over Sinoenergy’s closing price of $1.28 per share on Friday.
Sinoenergy’s board of directors approved the merger upon the recommendation of a special committee of the board consisting solely of independent directors. Brean Murray, Carret & Co. served as financial advisor to the Company in this transaction and rendered a fairness opinion to the special committee with respect to the transaction.
The deal is subject to the approval of majority shareholders and customary closing conditions.

The merger comes after a tumultuous year for Sinoenergy, which recorded a total loss for the second quarter of more than $2 million. The loss was due in part to an operating loss of $1 million and more than $1.1 million in losses from unpaid rent from lessee Qingdao Mingcheng Real Estate, Co., which leased a downtown facility from Sinoenergy for a three year term at RMB 40 million per-year. Sinoenergy had received only one payment of RMB 10 million from Qingdao Mincheng.

“We understand that there are serious problems with Mingcheng’s operations and investments in the current tough real estate market,” said Sinoenergy CEO Bo Huang in March.

“While we are striving to improve our operations, and hoping for an upturn after the challenging second quarter, but as the Mingcheng case illustrates, the Company is subject to domestic and even global economic conditions that are beyond our control.”

Buzz Stock of the Day – Novogen (NVGN)

Wednesday, July 8th, 2009

Shares of Australian pharmaceutical company Novogen Ltd. (Nasdaq: NVGN) continued their climb today after closing up 24 percent on the day yesterday.

Shares were up as much as 83 percent presumably another run on yesterday’s news that researchers found that the investigational anti-tumor drug, phenoxodiol, to be effective in killing cancer cells.
[–quote–]
Phenoxodiol is licensed by Marshall Edwards (Nasdaq: MSHL), which is majority owned by Novogen Ltd.

The results make phenoxodiol a promising candidate for the treatment of pathologically activated lymphocytes such as those in acute lymphoid leukemia, or diseases driven by T-cell proliferation such as autoimmune diseases and graft-versus-host disease, according to an article published in the Haematologica Journal on June 16.


Buzz Stock of the Day – Marshall Edwards (MSHL)

Tuesday, July 7th, 2009

Shares of Australian oncology company Marshall Edwards, Inc. (Nasdaq: MSHL) were up as much as 52 percent today after researchers found that the company’s chemosensitizing agent, Phenoxodiol has been shown to kill cancer cells.

“These findings indicate that phenoxodiol may have utility against autoimmune diseases, such as rheumatoid arthritis and psoriasis, as well as having potential in management of graft rejection in transplantation patients,” said Prof. Alan Husband, Group Director of Research, Marshall Edwards, Inc.

Researchers at the Malaghan Institute of Medical Research in Wellington, New Zealand found that abnormally proliferating human T-cells, rapidly dividing cancer cells such as primary myeloid and lymphoid leukemic blast cells undergo programmed cell death when exposed briefly to phenoxodiol.

Phenoxodiol is being developed to be used in combination with platinum drugs for late stage, chemoresistant ovarian cancer and as a monotherapy for prostate and cervical cancers.

The treatment is currently being investigated as a therapy for late-stage, chemoresistant ovarian, prostate and cervical cancers and as received Fast Track status from the FDA to facilitate its development as a therapy for recurrent ovarian and prostate cancers.

Phenoxodiol is part of a new breed of oncology drugs – multiple signal transduction regulators (abbreviated as ‘MSTR‘) — that act against the fundamentals of the cancer process, and has shown to kill virtually all types of cancer cells to which it has been exposed in the test tube, according to Marshall Edwards’ Web site. This includes breast, prostate, ovarian, lung, colorectal and head & neck carcinomas, mesotheliomas, leukemias, rhabdomyosarcoma and neuroglioma.

Buzz Stock of the Day – Patrick Industries (PATK)

Monday, July 6th, 2009

Shares of Patrick Industries, Inc. (Nasdaq: PATK) were up more than 40 percent today. The company manufactures building products and materials to manufactured housing and recreational vehicle market in the United States and Canada.

Last week, the Institute for Supply Management said its index of manufacturing activity moved to 44.8 in June from 42.8 in May. That reading was in line with the 45 reading expected by economists and signals a slowing rate of contraction. And a gauge of future U.S. housing-market activity rose for the fourth consecutive month in May, marking its longest stretch of growth since October 2004. The National Association of Realtors said its index of pending sales increased 0.1% in May to 90.7.

The Elkhart, Ind.-based Patrick Industries has been trading higher since July 1st, when the data was published.

A turnaround in the housing market is exactly what Patrick Industries needs. The company’s first quarter net sales was a mere $44.9 million compared to $97.0 million in 2008. “Our operating plans reflect the impact of lower sales volumes stemming from the recession and low consumer confidence that we believe will continue for at least the next nine to twelve months,”said Patrick Industries’ president and CEO, Todd Cleveland in a statement.

Click here to sign up for free micro-cap picks from the best newsletters on the Street.